Keeping Track: Cardio-Renal Drugs At Heart Of US FDA’s March Approval Binge

 
• By Bridget Silverman
Keeping Track Feature image
The US FDA approved seven new molecular entities and novel biologics in March. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers